Gut health spans barrier function, motility, immune signaling, inflammation, nutrient handling and the microbiome. A compound can affect one part of that system without improving the whole—and mechanistic plausibility should not be mistaken for demonstrated clinical benefit.
Barrier biology, inflammatory pathways and animal colitis models can be informative. They are not interchangeable with symptom relief or disease control in humans.
The cleanest way to evaluate GI claims is to separate the biological layer being targeted from the actual human outcome that matters.
This category contains both established peptide-based GI therapeutics and compounds such as KPV and BPC-157 that attract strong community interest despite much thinner human evidence.
A short peptide fragment associated with melanocortin biology and anti-inflammatory research, with most enthusiasm running ahead of clinical evidence.
A synthetic peptide with extensive preclinical interest around tissue repair and GI biology, but limited reliable human evidence.
An endogenous proglucagon-derived peptide with major effects on intestinal growth and function; analog drugs are used in short-bowel syndrome.
A GLP-2 analog approved for adults and certain pediatric patients with short bowel syndrome who are dependent on parenteral support.
A uroguanylin analog approved for chronic idiopathic constipation and IBS-C in adults.
A guanylate cyclase-C agonist peptide approved for IBS-C and chronic idiopathic constipation.
Evidence scores are editorial orientation, not treatment rankings. Approved GI therapies should not be conflated with experimental peptides simply because both act somewhere in the gastrointestinal system.
KPV and BPC-157 are increasingly discussed around inflammation, bloating, barrier function and recovery. The volume of those reports is much larger than the controlled human evidence supporting those uses.
Gut health is one of the clearest examples of why the publication has to extend beyond the Peptide Index.
Future coverage can follow fiber and nutrition, microbiome testing, elimination diets, motility, probiotics, prebiotics, inflammatory bowel disease therapies, IBS science, metabolic-gut signaling and diagnostics.
Interesting preclinical anti-inflammatory biology with almost no direct human therapeutic evidence.
One of the largest gaps on the site between online adoption and controlled human evidence.
An important counterexample: peptide biology can become real GI medicine when the indication, formulation and human outcomes are clearly defined.
Compare Human Evidence, Community Signal, The Gap and regulatory status across the broader library.